The Liraglutide In Ventricular Enhancement (LIVE) [5] and Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) [6] trials did not show a significant effect of liraglutide on CV outcomes in patients with HFrEF. This evidence concerns the gene GLP1R and heart failure.